Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.62 |
| ▸ | ALB | P02768 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | DHFR | P00374 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380998 | 1.00 | TTR (1.00) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5376489 | 0.87 | TTR (0.77) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL14408188 | 0.84 | TTR (0.72) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5380992 | 0.83 | TTR (0.71) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL11411645 | 0.82 | TTR (0.70) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5376518 | 0.82 | TTR (0.69) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5369440 | 0.81 | TTR (0.67) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5373126 | 0.80 | TTR (0.67) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5379885 | 0.80 | TTR (0.66) | TTRACMSDALBKDM4EMEN1 | |
| SCHEMBL5379887 | 0.80 | TTR (0.66) | TTRACMSDALBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016521-A1 | COMPOUND FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2025-01-23 | — | — | WO | claimed |
| US-11564899-B2 | Therapy for transthyretin-associated amyloidosis | SOM INNOVATION BIOTECH, S.L. (ES) | 2023-01-31 | — | — | US | claimed |
| EP-4731618-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025016521-A1 | COMPOUND FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024263751-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION AND TTR AMYLOIDOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240150297-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4291191-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-11564899-B2 | Therapy for transthyretin-associated amyloidosis | SOM INNOVATION BIOTECH, S.L. (ES) | 2023-01-31 | — | — | US | disclosed |
| US-11564899-B2 | Therapy for transthyretin-associated amyloidosis | SOM INNOVATION BIOTECH, S.L. (ES) | 2023-01-31 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-08-25 | — | — | US | disclosed |
| WO-2022173904-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4029859-A1 | 2-OXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-07-20 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | TTR 1/4885ACMSD 3319/4885ALB 6/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TTR 3722/4885ACMSD 305/4885ALB 1826/4885 |
| US-11564899-B2 | Therapy for transthyretin-associated amyloidosis | COMT, TTR, GSTM1 | TTR 2/4885ACMSD 3458/4885ALB 193/4885 |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | TTR 1/4885ACMSD 3319/4885ALB 6/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | TTR 1510/4885ACMSD 1010/4885ALB 920/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | TTR 3722/4885ACMSD 305/4885ALB 1826/4885 |
| US-20240150297-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, APOB, TSHR | TTR 1/4885ACMSD 4600/4885ALB 74/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | TTR 1510/4885ACMSD 1010/4885ALB 920/4885 |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | TTR 1/4885ACMSD 3319/4885ALB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.